CDP 571

Also Known As:

BAY 103356; BAY W 3356; BAY-103356; BAY-W 3356; BAY-W-3356; CDP-571; Humicade

Networked: 8 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        CDP 571: 8
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        CDP 571: 8
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        CDP 571: 8

Experts

1.	Lichtenstein, Gary R: 1 article (06/2007)
2.	Osterman, Mark T: 1 article (06/2007)
3.	Kale-Pradhan, Pramodini B: 1 article (10/2006)
4.	Osiecki, Lisa L: 1 article (10/2006)
5.	Taylor, Jason D: 1 article (10/2006)
6.	Wilhelm, Sheila M: 1 article (10/2006)
7.	Armuzzi, Alessandro: 1 article (07/2006)
8.	Danese, Silvio: 1 article (07/2006)
9.	Gasbarrini, Antonio: 1 article (07/2006)
10.	Papa, Alfredo: 1 article (07/2006)

Related Diseases

1.	Crohn Disease (Crohn's Disease) 10/01/2006 - "Several studies have shown that CDP 571 decreases the Crohn's Disease Activity Index score and is promising, especially in patients with refractory disease. " 01/01/2003 - "In January 2002, AFX (Agence France-Presse and the Financial Times Group) reported that analysts at Morgan Stanley have forecast Humicade trade mark to reach sales of 250 million US dollars in 2008--at that time, the market value for anti-TNF products to treat rheumatoid arthritis and Crohn's disease will exceed 4 billion US dollars, according to Morgan Stanley." 03/01/1999 - "Among these, infliximab and CDP 571 are perhaps the most promising, particularly in Crohn's disease. " 06/01/2007 - "Less impressive results were seen in randomized controlled trials involving CDP-571, etanercept, or onercept for patients with Crohn's disease. " 07/01/2006 - "Infliximab (an IgG1 mouse/human chimeric monoclonal anti-TNF-alpha antibody fragment) is the most efficacious compound in induction and maintenance therapy of active and fistulizing Crohn's disease, being at present the only biological compound approved for therapy, but with the limit of the immunogenicity; CDP-571 (a humanized anti-TNF-alpha antibody) and CDP-870 (a PEGylated anti-TNF-alpha antibody) are less immunogenic, showed some efficacy in induction therapy in Crohn's disease but a rapid loss of response in maintenance therapy. "
2.	Septic Shock (Toxic Shock Syndrome) 01/01/2003 - "Celltech Group is no longer developing CDP 571 for septic shock, based on negative results with the related compound nerelimomab. "
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2003 - "Celltech also plans to investigate the use of CDP 571 in psoriasis via a collaboration with Biogen (USA). "
4.	Necrosis 01/01/2003 - "CDP 571 [anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade] is a recombinant humanised antibody directed against tumour necrosis factor (TNF). "
5.	Rheumatoid Arthritis 01/01/2003 - "In January 2002, AFX (Agence France-Presse and the Financial Times Group) reported that analysts at Morgan Stanley have forecast Humicade trade mark to reach sales of 250 million US dollars in 2008--at that time, the market value for anti-TNF products to treat rheumatoid arthritis and Crohn's disease will exceed 4 billion US dollars, according to Morgan Stanley."

Related Drugs and Biologics

1.	Etanercept (Enbrel)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Thalidomide (Thalomid)
4.	Interleukin-11 (Interleukin 11)
5.	Interleukin-10 (Interleukin 10)
6.	Antibodies
7.	recombinant human tumor necrosis factor-binding protein-1
8.	Infliximab (Remicade)
9.	Monoclonal Antibodies
10.	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)

Related Therapies and Procedures

1.	Therapeutics